Could sodium channel blockers replace opioid pain medications?
The U.S. Food and Drug Administration (FDA) recently approved Journax™ (suzetrigine) for moderate to-severe acute pain. This is the first approved drug in a class of medications known as sodium channel blockers. It offers a new, but pricier, option for acute pain management.
If this medication gains additional indications for chronic pain, it will significantly affect future spending. Get details on how this newly approved painkilling drug is offering prescribers a long-waited alternative to opioid pain medications and what it means for plan sponsors.
Related healthcare insights
Article
Discover our latest innovation to the PA process — PreCheck Prior Authorization — which reduces approval times, appeals and denials.
Report
Our report emphasizes new, next-gen and first-in-class treatments for cystic fibrosis, non-opioid treatment and GLP-1 drugs.
E-book
Explore the dramatic changes in the years since 2000 — in drug performance and design, and especially affordability.